# GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

> **NCT01356160** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 351 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** GS-5885
- **DRUG:** GS-9451
- **BIOLOGICAL:** peginterferon alfa-2a
- **DRUG:** ribavirin tablet
- **DRUG:** GS-9451 Placebo

## Key facts

- **NCT ID:** NCT01356160
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 351 (ACTUAL)
- **Last updated:** 2014-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01356160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01356160, "GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01356160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*